Tailored antithrombotic therapy, ranging from standard aspirin to intensified dual regimens, is essential to ensure graft patency and improve prognosis after coronary artery bypass grafting.
What are the optimal antithrombotic treatment strategies to improve prognosis and preserve grafts in patients undergoing coronary artery bypass grafting?
This review summarizes optimal antithrombotic strategies, including aspirin and intensified regimens, to maintain graft patency and improve outcomes post-CABG across diverse patient profiles.
Absolute Event Rate: 0% vs 0%
Antithrombotic therapy is an integral component of treatment designed to ensure long-term patency of grafts and improve prognosis in patients undergoing coronary artery bypass grafting. The authors review optimal antithrombotic treatment strategies for different categories of patients — those with stable coronary artery disease, acute coronary syndromes, concomitant atrial fibrillation, and heart valve disease. A particular attention is paid to clinical situations associated with high risk of graft failure (complex coronary reconstructions, “compromised” distal bed, coronary endarterectomy). Standard aspirin monotherapy and various options for “intensified” treatment, including addition of the second antithrombotic drug (P2Y12 receptor blocker or anticoagulant), are considered.
Komarov et al. (Thu,) reported a other. Tailored antithrombotic therapy, ranging from standard aspirin to intensified dual regimens, is essential to ensure graft patency and improve prognosis after coronary artery bypass grafting.